Clinical Trial Update: Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 study evaluated the combination of copanlisib, a PI3K inhibitor, with nivolumab in relapsed/refractory microsatellite-stable solid tumors and MSS co…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Copanlisib (copanlisib)
• nivolumab (nivolumab)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Unresectable or Metastatic Microsatellite Stable (MSS) Solid Tumor, Microsatellite Stable (MSS) Colon Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2023-06-15